Results 51 to 60 of about 161,099 (267)
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Hypertrophic cardiomyopathy is associated with alterations in coronary microvascular function which have variable pathophysiologic mechanisms, and variable reversibility acutely and chronically following alcohol septal ablation (ASA).
Vojko V. Misevic +12 more
wiley +1 more source
Coronary Perforation During Excimer Laser Angioplasty in a Patient With Prior Thoracic Radiotherapy
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Management of heavily calcified coronary lesions remains challenging despite advances in plaque‐modifying technologies. Excimer laser coronary angioplasty (ELCA) is an effective adjunctive strategy with a low risk of no‐reflow. Case Summary A 75‐year‐old woman with non–ST‐segment elevation acute coronary syndrome and severe left ...
Francesco Maria Sparasci +3 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background There are limited data evaluating the association between operator−patient sex, and outcomes in patients undergoing percutaneous coronary intervention (PCI). Methods We included 138,112 consecutive PCI procedures in patients presenting with acute coronary syndrome (ACS) in England and Wales, 2017−2020.
Sharon A. Ayayo +6 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Heavily calcified coronary lesions remain a major challenge in percutaneous coronary intervention (PCI), often limiting the effectiveness of intravascular lithotripsy (IVL). We report a five‐case series in which IVL failed to achieve adequate lesion modification but was successfully augmented by the addition of one or more buddy wires.
Alfredo Marchese +5 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Physiology‐Guided Drug‐Coated Balloon Angioplasty: What We Know and What is Yet to be Understood
Catheterization and Cardiovascular Interventions, EarlyView.
Marco Frazzetto +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka +16 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source